PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
-2.53%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$2.17B
AUM Growth
+$2.17B
(-8.4%)
Cap. Flow
-$68.3M
Cap. Flow
% of AUM
-3.15%
Top 10 Holdings %
Top 10 Hldgs %
36.12%
Holding
88
New
9
Increased
22
Reduced
22
Closed
13
Top Buys
| 1 |
Becton Dickinson
BDX
|
$37.4M |
| 2 |
DexCom
DXCM
|
$33.5M |
| 3 |
Legend Biotech
LEGN
|
$22.8M |
| 4 |
Acadia Healthcare
ACHC
|
$22.5M |
| 5 |
Ascendis Pharma
ASND
|
$21.7M |
Top Sells
| 1 |
Cigna
CI
|
$46.8M |
| 2 |
Biogen
BIIB
|
$43.1M |
| 3 |
AstraZeneca
AZN
|
$39.1M |
| 4 |
Axsome Therapeutics
AXSM
|
$30M |
| 5 |
Agilent Technologies
A
|
$27.5M |
Sector Composition
| 1 | Healthcare | 95.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
51
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $11.9M | 0.52% |
+318,948
| New | +$11.9M |
|
52
Generation Bio
GBIO
$40.3M
| $11.4M | 0.5% |
2,648,297
-254,895
| -9% | -$1.1M |
|
53
Procept Biorobotics
PRCT
$2.2B
| $9.08M | 0.4% |
319,782
-197,744
| -38% | -$5.62M |
|
54
Editas Medicine
EDIT
$222M
| $7.55M | 0.33% |
1,040,794
-425,938
| -29% | -$3.09M |
|
55
Immunovant
IMVT
$2.63B
| $7.17M | 0.32% |
+462,431
| New | +$7.17M |
|
|
ADAP
56
Adaptimmune Therapeutics
ADAP
$15.3M
| $6.53M | 0.29% |
5,992,571
+1,149,061
| +24% | +$1.25M |
|
57
Outset Medical
OM
$244M
| $5.98M | 0.26% |
+324,982
| New | +$5.98M |
|
58
Werewolf Therapeutics
HOWL
$59.4M
| $5.76M | 0.25% |
2,217,220
+923,927
| +71% | +$2.4M |
|
59
Xenon Pharmaceuticals
XENE
$3.03B
| $3.58M | 0.16% |
100,147
+82,659
| +473% | +$2.96M |
|
60
Celcuity
CELC
$2.27B
| $3.19M | 0.14% |
310,965
-401,146
| -56% | -$4.11M |
|
|
BLU
61
DELISTED
BELLUS Health Inc.
BLU
| $3.17M | 0.14% |
439,813
+375,949
| +589% | +$2.71M |
|
|
VERV
62
DELISTED
Verve Therapeutics
VERV
| $2.68M | 0.12% |
186,087
-31,215
| -14% | -$450K |
|
|
CMPS
63
Compass Pathways
CMPS
$434M
| $2.44M | 0.11% |
246,064
-263,561
| -52% | -$2.62M |
|
|
INBX
64
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $2.29M | 0.1% |
+121,447
| New | +$2.29M |
|
65
PMV Pharmaceuticals
PMVP
$79M
| $1.99M | 0.09% |
418,027
+84,311
| +25% | +$402K |
|
66
Praxis Precision Medicines
PRAX
$946M
| $1.76M | 0.08% |
2,176,594
-600,873
| -22% | -$486K |
|
|
VECT
67
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $1.12M | 0.05% |
131,922
+106,381
| +417% | +$905K |
|
68
IO Biotech
IOBT
$110M
| $952K | 0.04% |
507,640
| – | – |
|
69
Keros Therapeutics
KROS
$638M
| $869K | 0.04% |
20,350
+4,351
| +27% | +$186K |
|
70
Iovance Biotherapeutics
IOVA
$792M
| $868K | 0.04% |
142,055
+128,718
| +965% | +$786K |
|
71
Sana Biotechnology
SANA
$721M
| $45.7K | ﹤0.01% |
13,966
-48,810
| -78% | -$160K |
|
|
72
Agilent Technologies
A
$35.6B
| – | – |
-183,504
| Closed | -$27.5M |
|
|
73
AstraZeneca
AZN
$249B
| – | – |
-576,800
| Closed | -$39.1M |
|
74
Biohaven
BHVN
$1.68B
| – | – |
-10,988
| Closed | -$153K |
|
|
75
Biogen
BIIB
$20.5B
| – | – |
-155,659
| Closed | -$43.1M |
|